

# Covid-19 ve Merkezi Sinir Sistemi Tutulumu Patofizyoloji, Klinik Tablolar ve Güncel Yaklaşım

## 5. BÖLÜM

Taner ENGİN<sup>1</sup>

M. Onur YÜKSEL<sup>2</sup>

### GİRİŞ

Aralık 2019'da Çin'de Wuhan şehrinde Oftalmolog Dr. Li Wenliang tarafından ciddi bir akut respiratuvar sendrom benzeri bir tabloya yol açan solunum sistemi hastalığı bildirildi. Bu hastalığın tablosunda etkenin tam olarak belirlenemediği ancak hızlı ilerleyen klinik bulgulara yol açtığı ve gidişatının son derece kötü olduğu ifade edildi (1). 7 Ocak 2020 tarihinde ise **Dünya Sağlık Örgütü (DSÖ)** tarafından hastadan izole edilen viral materyalin genetik incelenmesi sonucu bu tabloya yol açan ajanın **Ciddi Akut Respiratuvar Sendrom (SARS)** ve **Orta Doğu Respiratuvar Sendromu (MERS)** benzeri tablolara yol açan koronavirüs'ün yeni bir tipi olduğu belirtilerek **ciddi akut respiratuvar sendrom koronavirüs 2 (SARS-CoV-2)** olarak adlandırılmıştır. (2,3,4). 30 Ocak 2020'de DSÖ bu durumu halk sağlığı için bir tehdit olarak ilan ederek her 2,4 günde bir hasta sayısının iki katına çıktığını ve tanı konan her bireyin 4,7-6,6 kişiye bu hastalığı bulaştırdığını ifade etmiştir (4).

11 Mart 2020 tarihinde DSÖ bu hastalığı dünyada 215'ten fazla ülkede ve 3.181.642 hastada görüldüğünü açıklayarak **Koronavirüs Hastalığı (COVID-19)** olarak tanımlamış ve pandemi olarak ilan etmiştir (2). Nitekim aynı tarihte Türkiye Cumhuriyeti Sağlık Bakanlığı tarafından ülkemizde ilk defa bir hastaya COVID-19 tanısı konulduğunu açıklanmıştır (5). 1 Nisan 2020 tarihinde ise Türkiye'de tüm illerde COVID-19 hastalığının görüldüğü resmi olarak bildirilmiştir (6). Akabinde devamlı artan vaka sayıları nedeniyle ciddi önlemler alınmış, kısıtlamalara gidilerek ve yasaklar ilan edilmesi gibi önlemlerle vaka sayısı-

<sup>1</sup> Uzm. Dr. TC SBÜ Mehmet Akif İnan Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği drtanerengin@gmail.com

<sup>2</sup> Uzm. Dr. Medipol Üniversitesi Tıp Fakültesi, Beyin ve Sinir Cerrahisi Kliniği dr.onur\_yksl@hotmail.com

**KAYNAKÇA**

1. Petersen E, Hui D, Hamer DH, Blumberg L, Madoff LC, Pollack M et al. Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak. *Int J Infect Dis* 2020 Apr;93:205-207.
2. Berger JR. COVID-19 and the nervous system *J Neurovirol*. 2020 Apr;26(2):143-148.
3. Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. *Am J Em Med*. 2020 Jul;38(7):1549.e3-1549.e7.
4. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2020 Jul;26(7):1470-1477.
5. Sağlık Bakanı Koca Türkiye'de ilk koronavirüs vakasının görüldüğünü açıkladı". *Anadolu Ajansı*. 11 Mart 2020. <https://www.aa.com.tr/tr/koronavirus/saglik-bakani-koca-turkiyede-ilk-koronavirus-vakasinin-gorulduğunu-acikladi/1761466>.
6. Bakan Koca açıkladı! Türkiye'de can kaybı 44'e yükseldi". *CNN Türk* <https://www.cnnturk.com/turkiye/bakan-koca-acikladi-turkiyede-can-kaybi-44e-yukseldi>.
7. Bulut C, Kato Y. Epidemiology of COVID-19. *Turk J Med Sci*. 2020 Apr 21;50(SI-1):563-570.
8. Cases in the U.S. CDC. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. (Accessed 2 May 2020).
9. WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int/> (Update Date:2020/09/23).
10. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası. Güncelleme Tarihi: 23 Eylül 2020. <https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html>.
11. Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, Manousakis G. Neurological involvement of coronavirus disease 2019: a systematic review. *J Neurol*. 2020 Jun 19;1-19.
12. Clayton AW. Emergent Viral Infections of the CNS. *J Neuropathol Exp Neurol*. 2020 Aug 1;79(8):823-842.
13. Cataldi M, Pignataro G, Tagliatela M. Neurobiology of coronaviruses: Potential relevance for COVID-19. *Neurobiol Dis*. 2020 Sep;143:105007.
14. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. *Adv Virus Res*. 2011;81:85-164.
15. Perlman S. Another Decade, Another Coronavirus. *N Engl J Med*. 2020 Feb 20;382(8):760-762.
16. Niu J, Shen L, Huang B, Ye F, Zhao L, Wang H, Deng Y, Tan W. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. *Antiviral Res*. 2020 Jan;173:104646.
17. Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. *Acta Neurol Taiwan*. 2005 Sep;14(3):113-9.
18. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett*. 2002 Dec 4;532(1-2):107-10.
19. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 2020 Mar 13;367(6483):1260-1263.

20. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med* 2020 Mar 19;382(12):1177-1179.
21. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. *Cell Host Microbe*. 2013 Apr 17;13(4):379-93.
22. von Bernhardi R. Glial cell dysregulation: a new perspective on Alzheimer disease. *Neurotox Res*. 2007 Dec;12(4):215-32.
23. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S. Front. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. *Immunol*. 2020 Jul 10;11:1648.
24. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res*. 2020 Feb 6;7(1):4.
25. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun*. 2020 Jul;87:18-22.
26. Morassi M, Bagatto D, Cobelli M, D'Agostini S, Gigli GL, Bnà C, Vogrig A. J Stroke in patients with SARS-CoV-2 infection: case series. *Neurol*. 2020 Aug;267(8):2185-2192. *Neurol Neuroimmunol Neuroinflamm*. 2020 Jul 1;7(5):e821.
27. Increased CSF levels of IL-1 $\beta$ , IL-6, and ACE in SARS-CoV-2-associated encephalitis
28. Bodro M, Compta Y, Llánsó L, Esteller D, Doncel-Moriano A, Mesa A et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. J Virol*. 2008 Aug;82(15):7264-75.
29. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020 Feb 22;395(10224):565-574.
30. Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. *Virus Res*. 2008 Apr;133(1):4-12.
31. Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. *Ann Neurol*. 2018 Jan;83(1):166-177.
32. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020 Jun 1;77(6):683-690.
33. Al-Olama M, Rashid A, Garozzo D. COVID-19-associated meningoencephalitis complicated with intracranial hemorrhage: a case report. *Acta Neurochir (Wien)*. 2020 Jul;162(7):1495-1499.
34. González-Pinto T, Luna-Rodríguez A, Moreno-Estébanez A, Agirre-Beitia G, Rodríguez-Antigüedad A, Ruiz-Lopez M. Emergency room neurology in times of COVID-19: malignant ischaemic stroke and SARS-CoV-2 infection. *Eur J Neurol*. 2020 Apr 30;10.1111/ene.14286.
35. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res*. 2020 Jul;191:9-14.

36. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020 Jul;191:145-147.
37. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *Engl J Med.* 2020 May 14;382(20):e60.
38. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *Thromb Haemost.* 2020 Jul;18(7):1559-1561.
39. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C et al. Neurologic Features in Severe SARS-CoV-2 Infection. *Engl J Med.* 2020 Jun 4;382(23):2268-2270.
40. Carlos Manuel Romero-Sánchez, Inmaculada Díaz-Maroto, Eva Fernández-Díaz, Álvaro Sánchez-Larsen, Almudena Layos-Romero, Jorge García-García et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBA-COVID registry *Neurology.* 2020 Aug 25;95(8):e1060-e1070.
41. Tang N, Li D, Wang X, Sun Z.J. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Thromb Haemost.* 2020 Apr;18(4):844-847.
42. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. *Thromb Haemost.* 2020 Jun;120(6):949-956.
43. Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. *Transl Stroke Res.* 2020 Jun;11(3):322-325.
44. Agarwal A, Pinho M, Raj K, Yu FF, Bathla G, Achilleos Met al. Neurological emergencies associated with COVID-19: stroke and beyond. *Emerg Radiol.* 2020 Aug 11;1-8.
45. Hoelscher C, Sweid A, Ghosh R, Saiegh FA, Keppetipola KM, Farrell CJ et al. Cerebral deep venous thrombosis and COVID-19: case report. *J Neurosurg.* 2020 Sep 4;1-4.
46. Ellul M, Solomon T. Acute encephalitis - diagnosis and management. *Clin Med (Lond).* 2018 Mar;18(2):155-159.
47. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. *Brain Behav Immun.* 2020 Aug;88:945-946.
48. Rossi A. Imaging of acute disseminated encephalomyelitis. *Neuroimaging Clin N Am.* 2008 Feb;18(1):149-61; ix.
49. Wong AM, Simon EM, Zimmerman RA, Wang HS, Toh CH, Ng SH. Acute necrotizing encephalopathy of childhood: correlation of MR findings and clinical outcome. *AJNR Am J Neuroradiol.* 2006 Oct;27(9):1919-23.
50. Efe IE, Aydin OU, Alabulut A, Celik O, Aydin K. COVID-19-Associated Encephalitis Mimicking Glial Tumor. *World Neurosurg.* 2020 Aug;140:46-48.
51. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* 2020 Jun 6;395(10239):1763-1770.
52. Scullen T, Keen J, Mathkour M, Dumont AS, Kahn L. Coronavirus 2019 (COVID-19)-Associated Encephalopathies and Cerebrovascular Disease: The New Orleans Experience. *World Neurosurg.* 2020 Sep;141:e437-e446.

53. Benameur K, Agarwal A, Auld SC, Butters MP, Webster AS, Ozturk T et al. Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020. *Emerg Infect Dis.* 2020 Sep;26(9):2016-2021.
54. Zhang T, Hirsh E, Zandieh S, Rodricks MB. COVID-19-Associated Acute Multi-infarct Encephalopathy in an Asymptomatic CADASIL Patient. *Neurocrit Care.* 2020 Oct 6.
55. Etemadifar M, Salari M, Murgai AA, Hajiahmadi S. Fulminant encephalitis as a sole manifestation of COVID-19. *Neurol Sci.* 2020 Sep 8:1-3
56. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis.* 2020 May;94:55-58.
57. Huang YH, Jiang D, Huang JT. SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis. *Brain Behav Immun.* 2020 Jul;87:149.
58. Dixon L, Varley J, Gontsarova A, Mallon D, Tona F, Muir D et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. *Neurol Neuroimmunol Neuroinflamm.* 2020 May 26;7(5):e789.
59. Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. *BMC Neurol.* 2020 Jun 18;20(1):248.
60. Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. *Neuroinflammation.* 2020 Aug 6;17(1):231.
61. Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S et al. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. *Ann Neurol.* 2020 May 17;10.1002/ana.25783.
62. Mardani M, Nadji SA, Sarhangipor KA, Sharifi-Razavi A, Baziboroun M. COVID-19 infection recurrence presenting with meningoencephalitis. *New Microbes New Infect.* 2020 Jul 23;37:100732.
63. Sohal S, Mansur M. COVID-19 Presenting with Seizures. *IDCases.* 2020 May 1;20:e00782.
64. Asadi-Pooya AA. Seizures associated with coronavirus infections. *Seizure.* 2020 Jul;79:49-52.
65. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. *Neuroepidemiology.* 2011;36(2):123-33.
66. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med.* 2020 Jun 25;382(26):2574-2576.
67. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol.* 2020 May;19(5):383-384.
68. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. *IDCases.* 2020 Apr 18;20:e00771.

69. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmun Rev.* 2020 Jun;19(6):102537.
70. Dalakas MC. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. *Neurol Neuroimmunol Neuroinflamm.* 2020 Jun 9;7(5):e781.
71. Domingues RB, Mendes-Correa MC, de Moura Leite FBV, Sabino EC, Salarini DZ, Claro I et al. First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. *J Neurol.* 2020 Jun 20:1-3.
72. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ.* 2020 Feb 19;368:m606.
73. Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. *J Neurol.* 2020 Jun;267(6):1573-1576.
74. Hao Li, Qun Xue, Xingshun Xu. Involvement of the Nervous System in SARS-CoV-2 Infection. *Neurotox Res.* 2020 Jun;38(1):1-7.
75. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. *Compr Physiol.* 2016 Mar 15;6(2):603-21
76. Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry.* 2020 Oct;7(10):875-882
77. Beach SR, Praschan NC, Hogan C, Dotson S, Merideth F, Kontos Net et al. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. *Gen Hosp Psychiatry.* 2020 Jul-Aug;65:47-53.
78. Rimmelink M, De Mendonça R, D'Haene N, De Clercq S, Verocq C, Lebrun L et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. *Crit Care.* 2020 Aug 12;24(1):495.
79. Bryce C, Grimes Z, Pujades E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of SARS-CoV2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. *medRxiv.* 2020.
80. Al-Sarraj S, Troakes C, Hanley B, Osborn M, Richardson MP, Hotopf M et al. The spectrum of neuropathology in COVID-19. *Neuropathol Appl Neurobiol.* 2020 Sep 16.
81. Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS et al. Neuropathological Features of Covid-19. *N Engl J Med.* 2020 Sep 3;383(10):989-992.
82. Vasquez-Bonilla WO, Orozco R, Argueta V, Sierra M, Zambrano LI, Muñoz-Lara F et al. A review of the main histopathological findings in coronavirus disease 2019. *Hum Pathol.* 2020 Aug 2:S0046-8177(20)30147-7.
83. Koralnik IJ, Tyler KL. COVID-19: A Global Threat to the Nervous System. *Ann Neurol.* 2020 Jul;88(1):1-11.
84. Kantonen J, Mahzabin S, Mäyränpää MI, Tynninen O, Paetau A, Andersson N et al. Neuropathologic features of four autopsied COVID-19 patients. *Brain Pathol.* 2020 Aug 6;10.1111/bpa.12889.

85. Stoyanov GS, Lyutfi E, Dzhenkov DL, Petkova L. Acute Necrotizing Encephalitis in Viral Respiratory Tract Infection: An Autopsy Case Report. *Cureus*. 2020 May 12;12(5):e8070.
86. Vargas-Gandica J, Winter D, Schnippe R, Rodriguez-Morales AG, Mondragon J, Juan Pablo Escalera-Antezana et al. Ageusia and anosmia, a common sign of COVID-19? A case series from four countries. *J Neurovirol*. 2020 Oct;26(5):785-789.
87. Han AY, Mukdad L, Long JL, Lopez IA. Anosmia in COVID-19: Mechanisms and Significance. *Chem Senses*. 2020 Jun 17:bjaa040
88. Kalia LV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. *Nat Rev Neurol*. 2016 Feb;12(2):65-6.
89. Imbriani P, D'Angelo V, Platania P, Di Lazzaro G, Scalise S, Salimei C et al. Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. *Parkinsonism Relat Disord*. 2020 May;74:57-63.
90. Marreiros R, Müller-Schiffmann A, Trossbach SV, Prikulis I, Hänsch S, Weidtkamp-Peters S et al. Disruption of cellular proteostasis by H1N1 influenza A virus causes  $\alpha$ -synuclein aggregation. *Proc Natl Acad Sci U S A*. 2020 Mar 24;117(12):6741-6751.
91. Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. *Neurobiol Dis*. 2018 Jan;109(Pt B):226-248.
92. Schirinzi T, Sancesario GM, Di Lazzaro G, Biticchi B, Colona VL, Mercuri NB et al. CSF  $\alpha$ -synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. *Parkinsonism Relat Disord*. 2019 Apr;61:203-206
93. Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. *Nat Commun*. 2019 Sep 2;10(1):3945.
94. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. *JAMA Neurol*. 2016 Nov 1;73(11):1316-1324
95. Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J. C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Front Neurol*. 2019 Apr 17;10:384.
96. van Langelaar J, Rijvers L, Smolders J, van Luijn MM. B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. *Front Immunol*. 2020 May 8;11:760
97. Soldan SS, Jacobson S (2016) Virus-induced demyelination: The case for virus(es) in multiple sclerosis. In: *Neurotropic Viral Infections, vol 2. Neurotropic Retroviruses, DNA Viruses, Immunity and Transmission*. Springer International Publishing, pp 175-220.
98. Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to *in vivo* imaging. *Neural Regen Res*. 2019 Mar;14(3):373-386.
99. Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. *JAMA Neurol*. 2020 Jun 26;77(9):1-10.

100. Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirus-myeelin cross-reactive T-cell clones derived from multiple sclerosis patients. *Clin Immunol.* 2007 Jun;123(3):258-67.
101. Xie J, Fan HW, Li TS, Qiu ZF, Han Y, Zhongguo Y, Xue Ke et al. [Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients]. *Bao.* 2006 Apr;28(2):253-5.
102. Cossarizza A, Biasi SD, Guaraldi G, Girardis M, Mussini C. SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. *Cytometry A.* 2020 Apr;97(4):340-343.
103. Rinaldi F, Federle L, Puthenparampil M, Perini P, Grassivaro F, Gallo P. Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy. *Neurol Neuroimmunol Neuroinflamm.* 2017 Dec 13;5(1):e420.
104. Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. *Eur J Neurol.* 2020 Apr 25;10.1111/ene.14277.